GSK (GSK) Projected to Post Earnings on Wednesday

Key Points

• GSK is anticipated to release its Q3 2025 earnings results on October 29th, with analysts predicting earnings of $1.22 per share and revenue of $8.2086 billion.
• The company recently reported a net margin of 10.81% and quarterly revenue of $10.64 billion, exceeding estimates of $7.92 billion.
• Following an upgrade by Wall Street Zen to a "strong-buy" rating, GSK currently holds a consensus rating of "Reduce" with a price target of $37.38.

GSK (NYSE:GSK - Get Free Report) is expected to release its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect GSK to post earnings of $1.22 per share and revenue of $8.2086 billion for the quarter. GSK has set its FY 2025 guidance at 4.590-4.590 EPS.Interested persons can find conference call details on the company's upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 8:00 AM ET.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. The business had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.GSK's quarterly revenue was up 1.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.43 earnings per share. On average, analysts expect GSK to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

GSK Stock Performance

NYSE GSK opened at $43.93 on Wednesday. The company has a market capitalization of $89.30 billion, a price-to-earnings ratio of 20.34, a PEG ratio of 1.99 and a beta of 0.53. GSK has a twelve month low of $31.72 and a twelve month high of $45.59. The stock has a fifty day simple moving average of $41.21 and a 200 day simple moving average of $39.13. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 9th. Investors of record on Friday, August 15th were issued a $0.4206 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 3.8%. The ex-dividend date was Friday, August 15th. GSK's dividend payout ratio is presently 78.24%.

Institutional Investors Weigh In On GSK

A number of hedge funds have recently modified their holdings of GSK. Gabelli Funds LLC grew its stake in GSK by 17.8% in the 2nd quarter. Gabelli Funds LLC now owns 7,960 shares of the pharmaceutical company's stock valued at $306,000 after buying an additional 1,200 shares in the last quarter. IHT Wealth Management LLC grew its stake in GSK by 12.1% in the 2nd quarter. IHT Wealth Management LLC now owns 14,736 shares of the pharmaceutical company's stock valued at $566,000 after buying an additional 1,589 shares in the last quarter. Empowered Funds LLC grew its stake in GSK by 2.1% in the 1st quarter. Empowered Funds LLC now owns 79,174 shares of the pharmaceutical company's stock valued at $3,067,000 after buying an additional 1,598 shares in the last quarter. Rhumbline Advisers grew its stake in GSK by 20.7% in the 2nd quarter. Rhumbline Advisers now owns 22,209 shares of the pharmaceutical company's stock valued at $853,000 after buying an additional 3,806 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in GSK by 1.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 401,777 shares of the pharmaceutical company's stock valued at $15,444,000 after buying an additional 4,855 shares in the last quarter. Institutional investors own 15.74% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on GSK. Wall Street Zen upgraded GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, September 5th. Weiss Ratings reiterated a "hold (c)" rating on shares of GSK in a report on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, GSK has a consensus rating of "Reduce" and a consensus price target of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.